Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV: RP) PR Newswire TORONTO, June 19, 2014 TORONTO, June 19, 2014 /PRNewswire/ - Ubika Research has recently published a new information report on RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF), a regenerative medicine company focused on developing autologous cell therapies for multi-billion dollar markets that address diseases caused by a deficit of healthy cells required for normal healing and function, such as chronic tendinosis, damaged skin and pattern baldness. Read the report here: http://www.smallcappower.com/reports/files/replicel-life-sciences-inc-research-report About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function such as chronic tendinosis, damaged skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies are designed to treat chronic tendinosis and damaged or aging skin respectively, using fibroblasts isolated from the sheath of the hair follicle. Another of the company's pipeline products, RCH-01 for the treatment of pattern baldness, is manufactured from cells derived from the hair follicle dermal cup. Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. All product candidates are based on RepliCel's innovative technology, which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits. For additional information please visitwww.replicel.com. To view the initiation research report, research bulletins, analyst commentaries and CEO video interview please visit:http://www.smallcappower.com/companies/products/replicel-life-sciences-tsxv-rp About Ubika Research Ubika Research is an investment research and capital market services firm based in Toronto with a proven track record of identifying and launching coverage of high potential small cap stocks (<$5 billion) at an early stage. For more information visit www.ubikaresearch.com Disclosure Ubika Research has received compensation from RepliCel Life Sciences Inc. to provide analyst research coverage. Except for the historical information presented herein, matters discussed in this document contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Ubika Research andwww.smallcappower.com(are both divisions of Ubika Corporation), and are not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this report. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: http://www.smallcappower.com/posts/small-cap-power-disclosure. SOURCE Ubika Research Contact: Vikas Ranjan, Managing Director, Email:email@example.com
Globalfoundries to Buy IBM's Chip Unit; IBM Sees Pretax Charge $4.7 Billion
Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV: RP)
Press spacebar to pause and continue. Press esc to stop.